Sections
| Title | Starting Page | Number of Pages |
|---|
| Animal Rule Allowed – First De-risking Event Down | 1 | 1 |
| Business model | 1 | 1 |
| Key catalyst and de-risking event achieved | 1 | 1 |
| Valuation of $1.14/share, previously $0.76/share | 1 | 1 |
| Table/Chart: Share Details | 1 | 1 |
| Graph: Share Performance (12 months) | 1 | 1 |
| Table/Chart: Historical earnings and RaaS’ estimates (in A $m unless otherwise stated) | 1 | 1 |
| RaaS Initiation Report | 1 | 1 |
| Island Pharmaceuticals RaaS Initiation Report | 1 | 1 |
| Upside Case | 1 | 1 |
| Downside Case | 1 | 1 |
| Catalysts | 1 | 1 |
| Company Contact | 1 | 1 |
| Table/Chart: RaaS Contact | 1 | 1 |
| *The analyst owns shares | 1 | 1 |
| Next Steps In The Galidesivir Programme For Marburg | 2 | 1 |
| Graph: Exhibit 1: Animal Rule pathway expedites the clinical trial process | 2 | 1 |
| Conservative case | 2 | 1 |
| Recent Outbreaks | 3 | 1 |
| Conservative case (CONT) | 3 | 1 |
| Financials And Valuation | 3 | 1 |
| Table/Chart: Exhibit 2: ILA base-case rNPV (in A $m unless otherwise stated) | 4 | 1 |
| Table/Chart: Exhibit 3: ILA Financial Summary | 5 | 1 |
| FINANCIAL SERVICES GUIDE | 6 | 1 |
| RaaS Research Group Pty Ltd | 6 | 1 |
| Corporate Authorised Representative, number 1248415, of | 6 | 1 |
| About Us | 6 | 1 |
| Our general advice service | 6 | 1 |
| How are we paid? | 6 | 1 |
| Associations and Relationships | 6 | 1 |
| Complaints | 6 | 1 |
| Disclosure | 7 | 1 |
